Valuation: Valneva SE Pref.

Market Cap 49Cr 54Cr 45Cr 41Cr 77Cr 5.08TCr 80Cr 542.86Cr 215.25Cr 2.72TCr 202.33Cr 198.03Cr 8.62TCr P/E 2026 *
-5.89x
P/E 2027 * 9.3x
Enterprise Value 62Cr 69Cr 58Cr 52Cr 98Cr 6.48TCr 101.39Cr 691.93Cr 274.36Cr 3.46TCr 257.89Cr 252.42Cr 11TCr EV / Sales 2026 *
4.13x
EV / Sales 2027 * 1.95x
Free-Float
89.58%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 29/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 20/12/2023
Director/Board Member 75 07/03/2013
Chairman 65 20/12/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 54Cr
-2.69%-0.48%+53.97%+66.82% 6.63TCr
+0.34%+3.28%+11.28%+95.96% 6.06TCr
+1.05%+1.88%+24.55%+90.15% 5.55TCr
+0.14%+2.35%+13.86%+111.94% 4.76TCr
-2.21%-2.47%+20.18%+28.81% 4.37TCr
-2.30%-10.40%+154.30%+707.36% 3.73TCr
+2.15%+1.42%+14.58%+48.71% 3.66TCr
+2.45%-3.55%+78.74%+60.79% 3.22TCr
+2.62%+5.90%-37.29%+386.59% 2.66TCr
Average +0.16%+0.05%+37.13%+177.46% 5TCr
Weighted average by Cap. -0.11%+0.20%+36.90%+153.10%

Financials

2026 *2027 *
Net sales 15Cr 17Cr 14Cr 13Cr 24Cr 1.57TCr 25Cr 167.58Cr 66Cr 838.26Cr 62Cr 61Cr 2.66TCr 28Cr 31Cr 26Cr 24Cr 45Cr 2.95TCr 46Cr 314.77Cr 124.81Cr 1.57TCr 117.32Cr 114.83Cr 5TCr
Net income -8.14Cr -8.98Cr -7.52Cr -6.79Cr -13Cr -846.46Cr -13Cr -90Cr -36Cr -452.16Cr -34Cr -33Cr -1.44TCr 5.3Cr 5.85Cr 4.9Cr 4.42Cr 8.34Cr 551.7Cr 8.63Cr 59Cr 23Cr 294.7Cr 22Cr 21Cr 935.48Cr
Net Debt 13Cr 15Cr 12Cr 11Cr 21Cr 1.4TCr 22Cr 149.07Cr 59Cr 745.69Cr 56Cr 54Cr 2.37TCr 6.29Cr 6.94Cr 5.81Cr 5.25Cr 9.89Cr 654.03Cr 10Cr 70Cr 28Cr 349.37Cr 26Cr 25Cr 1.11TCr
Projected Income Statement - Annual - Valneva SE Pref.
Logo Valneva SE Pref.
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Valneva SE Pref.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.568EUR
Average target price
6.200EUR
Spread / Average Target
+141.43%